Zocor (or Simvastatin) was first introduced in the market as a cholesterol lowering drug, which is an effective treatment to prevent many heart ailments. Zocor was approved by the FDA in 1991 and became the highest selling cholesterol-lowering drug on the market. However, after a vast array of side effects and complications attributed to the medication came to light, sales fell off at an alarming rate. Since then, studies have shown that serious muscle damage was the most prominent side effect shown. As a result of damage to muscles and other side effects, lawsuits have been filed against the manufacturer. Today we outline some of the case studies performed on Zocor.
A case study:
This was a study published in PLoS initiated by Peter Ghazal from Edinburgh further taken ahead by W. Sean Davidson from the University of Cincinnati. This study revealed the detailed structure of HDL and relation between cholesterol levels and chances of developing viral infections. Further the case focused on the relation between good cholesterol and the health of immune system. The focus then shifted to Zocor, a cholesterol lowering drug, which was linked as being the major cause for triggering myopathy, rhabdomyolysis which can further intensify by causing kidney failure and ILD disorders. The final verdict is still unrevealed, but this was a case that focused on bringing to the view of people severe life threatening complications of Zocor.
Zocor 80 mg- a pill that can induce severe complications like Rhabdomyolysis and Myopathy
This is concerning a warning issued in March 2010, which laid emphasis on Zocor’s negative effect along with Simcor and Vytorin, all three of which pack simvastatin. An update to the same was made in June 2010, verdicts are still unrevealed.
80 mg dose of simvastatin can trigger onset of fatal rhabdomyolysis
As per a report published on June 8th 2011, a ban should be levied on the sale of 80 mg dose of Zocor that is linked with serious muscle damage that can finally lead to development of fatal effects.
High dose of Zocor responsible for increased muscle injury in human
Issued on 19th March 2010, the study showed how the intake of Zocor in high dose is leading to development of rhabdomyolysis that eventually can turn into a fatal cause.
Based on the trail put forth by SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine), FDA levied a warning that was critical for healthcare experts that said high doses of Zocor pills should never be prescribed to patients.
Another aspect for this was released in March 2010, that was in reference to Potential Signals of Serious Risks / New Safety Information Identified by AERS, Second Quarter 2009.
Similar findings were seen with Baycol, which was another drug found to induce the occurrence of rhabdomyolysis, which was withdrawn completely from sale on August 8th, 2001.
Widely regarded as safe drugs, but there is a serious need to bring to the notice of all that in reality Zocor, one from the statin class, can prove fatal over time when administered constantly. A $20 billion industry, this will need large awareness in order to take strict measures and to actually reveal safety instructions that will stop the harm this is causing to the health and life of people.